Friday, November 22, 2024
11/22/2024
Congenital Cytomegalovirus (CMV) infection is a leading cause of birth defects and developmental disabilities in the U.S., affecting thousands of children each year. Notably, the majority of children acquire congenital CMV from non-primary maternal CMV infection rather than primary infection. Thus, determining the maternal serostatus in the field may further our understanding of the association between CMV infection status and worse pregnancy outcome, and risk stratify pregnant women during gestation. Current methods to detect maternal CMV serostatus are labor intensive and require sophisticated equipment, dedicated laboratory space, and trained technicians. We propose developing a point-of-care (POC) test for rapid screening of maternal CMV serostatus. A rapid, on-site test for CMV serostatus screening in biospecimens would: (1) allow for immediate counseling and confirmatory testing, and (2) avoid having to create new laboratory infrastructure for biospecimen testing. Alternatively, a rapid POC test that could be utilized during initial study screening visits would permit the efficient identification and enrollment for CMV vaccine testing.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).
